AKI is a condition where the kidneys are not able to make enough urine. Therefore, another way to remove waste from the body is needed. One way of removing waste from the body is called Continuous Kidney Replacement Therapy (CKRT). There are different types of CKRT, but all allow waste to be removed from your body because the kidneys can not do this any longer. Acute kidney injury can also cause your immune system to not work correctly and this may be one of the reasons that AKI is such a deadly condition. White blood cells, which are key parts of the immune system, are overactive in AKI and may be the reason the immune system doesn't work the way it should. The experimental device is a Selective Cytopheretic Device (SCD). It is a set of tubing and a cartridge that is connected in series to a CKRT circuit. The SCD binds and stops overactive white blood cells. The purpose of this study is to test if the SCD helps someone with AKI recover faster than without it.

The purpose of the study is to better understand the experience of loved ones whose family members were treated for violence injuries at MUSC, and what services could potentially be improved. This study will involve administering surveys to loved ones of patients who are treated for injuries due to intentional violence at MUSC. They will be recruited via flyers and information sheets. Survey questions will address perceptions of their loved ones healthcare experience, interactions with staff members, impact of the Turning the Tide Violence Intervention Program (TTVIP), what perceived needs they have, and what services have been provided. Responses of those that have loved ones who enrolled in TTVIP compared to those who did not will be compared to assess for differences.

This study is for adult patients that have been diagnosed with stage I non-small cell lung cancer (NSCLC). The purpose of this study is to evaluate whether a drug called cemiplimab, used in combination with other standard therapies (chemotherapy) is safe and effective in treating early stage NSCLC. Cemiplimab is a FDA approved drug, but its use in this study is investigational. Participants will undergo standard procedures such as blood collection for laboratory testing, physical exams, and imaging. In addition to standard of care treatment, blood will be collected for research purposes and cemiplimab will be administered. Risks of being in this study include side effects from the drugs (such as nausea, vomiting, and low blood counts), loss of confidentiality, and bruising and/or bleeding from blood draws. Participation in this study is expected to last approximately five (5) years.

This study will look at whether a topical medication called minocycline foam (AMZEEQ) can help treat confluent and reticulated papillomatosis (CARP), a skin condition that causes dark, scaly patches. We will also evaluate how safe the treatment is and how satisfied patients are with it. The study is open to participants ages 9 years and older.

Participants will apply minocycline foam to one side of the affected skin and a moisturizing cream (emollient) to the other side for 5 weeks. This allows us to compare the two treatments in the same person. After this period, participants may choose to continue using the minocycline foam on all affected areas.

During the study, participants will attend follow-up visits where photos of the skin will be taken and the condition of the skin will be evaluated. Participants will also complete brief surveys about how their skin condition affects their quality of life and how satisfied they are with the treatment. The research team will monitor treatment use and any side effects.

The goal of this study is to learn whether topical minocycline could be a safe and effective treatment option for CARP, potentially providing an alternative to oral antibiotics.

As a part of their 2nd year curriculum, OT students offer a virtual wellness program, for graduate students, aged 18+, who are parenting, and it is called Mom Era, Reclaimed. It is led by the students and facilitated by faculty. The program runs for 6 weeks and is designed to help student moms manage stress, feel more connected to themselves and others, and build daily routines that work better for their lives as both students and parents. This study seeks to learn whether this kind of program is helpful for student moms, so it can be improved and possibly offered to more students in the future.
Participating students will be surveyed at the beginning of the first session and then again at the end of the final session to measure change in their perceptions of their stress, wellbeing and occupational balance. Student moms do not have to participate in the survey to be a part of the the wellness group, the survey is optional and will not affect their participation in the larger group.

Epidermolysis Bullosa is a genetic disorder manifesting typically at birth comprising several genetic subtypes that manifest as blistering or erosion of the skin in response to little or no apparent trauma. This clinical study is being conducted for research purposes. The cream being studied has allantoin as the active ingredient and the aim of this study is to assess the long-term safety of this cream when applied to the skin of participants with Epidermolysis Bullosa. This study is an open label extension to study SD-007. The study will be conducted by the study doctor, in other words, the physician responsible for the clinical study at your child's study site. Your child's participation in the clinical study is expected to last for approximately 12 months and approximately eighty (80) children will participate in this study. There will be a total of five (5) study visits over the course of one year. Study visits 1, 3 and 5 will be in person and visits 2 and 4 will be telephone visits.

The purpose of this study is to determine if a drug called adalimumab can reduce or prevent emergence or progression of synuclein-related neurodegeneration, or nerve cell death, in people diagnosed with REM Sleep Behavior Disorder (RBD.) About 108 individuals, aged 50-80, will be enrolled in this study, half of whom will receive the active study drug and half of whom will receive placebo. Participants would receive 40 mg adalimumab, administered subcutaneously every 2 weeks or matching placebo for up to 2 years (96 weeks).

Treating autoimmune pulmonary alveolar proteinosis (aPAP) patients with molgramostim nebulizer solution focuses on improving how the lungs function and defend against infection. In this condition, the lungs struggle to clear a natural substance called surfactant, which can make breathing harder. A protein in the body called granulocyte macophage colony-stimulating factor (GM‑CSF) helps activate immune cells that keep the lungs clean and healthy. These cells play an important role in removing buildup and protecting against germs. Increasing their activity can help the lungs work more efficiently. It also helps reduce lung damage by boosting the number of these helpful cells. In addition, this protein supports the formation of certain blood cells that are important for overall health. Molgramostim is a man-made version of this natural protein. It is delivered directly into the lungs using a nebulizer, allowing it to work where it is needed most. Research studies have shown that this treatment is generally safe, well tolerated, and can improve symptoms in people with autoimmune PAP.

This is a research study to understand patterns of nicotine pouch use over time among three separate groups of people who: 1) co-use nicotine pouches and cigarettes, 2) co-use nicotine pouches and conventional smokeless tobacco (including chewing tobacco, dip, moist snuff, or snus), or 3) exclusively use nicotine pouches. This is a naturalistic survey study; there is nothing required or requested of participants other than to complete our surveys. Participants do not need to quit or reduce their pouch/smoking/smokeless tobacco product use if they do not want to. They do not need to travel for this study; it is completely remote, and they can participate from their home.
Participation in the study will take place over a period of 12 months in the form of: 1) Monthly Surveys (13 total), 2) Daily Diaries for the first 90 days, and 3) Follow-Up Diaries in each of the 7 days leading up to each monthly follow-up survey.

This study aims to pilot test a virtual mindfulness meditation program for pulmonary hypertension (PH) in preparation for larger testing. Individuals living with PH will be invited to learn mindfulness practices via videos and the MMPH app for 8 weeks.

They will provide feedback via surveys at four time points: before and after the intervention (PAHSS, EmPHass-10, PHQ-8, PCL-5, CAMS-R), and again 1 month and 2 months after. They will be asked to wear a wrist actigraphy device before and after the intervention.

Participants will provide their feedback via an interview about their experience after the intervention is complete.